Moderna (MRNA) Stock Rises 3.61% Today, Coronavirus Vaccine Results Are Still Months Away

UTC by Christopher Hamman · 3 min read
Moderna (MRNA) Stock Rises 3.61% Today, Coronavirus Vaccine Results Are Still Months Away
Photo: Unsplash

Moderna (MRNA) stock price has risen at the possibility of having a new coronavirus vaccine by the fall of this year. Trials are expected to have been completed in two months’ time.

Moderna Inc (NASDAQ: MRNA) stock price has risen slightly today. The stock price is up to $28.11 +0.98 (3.61%) intraday. This rise in stock price is attributed to the expected positive results from the Moderna COVID-19 vaccine. The first results could be available in two months. 

Analysts believe that the trials conducted with the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NAID) will complete testing for a potential vaccine soonest. 

Moderna (MRNA) Stock May Remain Up as the Company Has Great Reserves

Moderna (MRNA) it seems is also healthy cash-wise. This is with a stated $1.26 billion in cash, cash equivalents plus invested funds in 2019. It allows the biotech company to focus until the final approvals are gotten from the US FDA to release its vaccine for public consumption. This is why many investors are considering it to be a great buy. 

Approval for Vaccine Takes Time

While this may speed things up, several things still have to occur before a single case is put on the trials for the vaccine. While the vaccine will reportedly be available in the fall, it won’t be available to just about anybody. A doctors’ note is required first to confirm eligibility for the trial vaccine now known as mRNA-1273. Then an internal review board has to approve the application before FDA approval is granted.

 This process falls under the United States’ emergency-use authorization (EUA) procedures for getting medications and vaccines given to special cases. 

The bureaucracy and slow pace of things will slow things up. Very few people will eventually get the final FDA approvals. Already Gilead Sciences Inc (NASDAQ: GILD) has indicated an end to accepting EUA applications. This is because approvals won’t be ready by April when trials for Remdesivir would have been finished. Remdesivir has proven to be effective in the treatment of COVID-19 cases. Though it was designed to treat Ebola cases, it has shown effectiveness in treating COVID-19. 

Moderna mRNA-1273 May Become the World’s Soonest Coronavirus Vaccine

As such, many people are wondering if Moderna delivers its in time. The truth is that this would probably be the first time that a vaccine will come out in the shortest space of time. Moderna (MRNA) CEO Stephane Mancel had already indicated that the vaccine will be available in the fall. This places the biotech company to be among the most innovative in the U.S. and global biotech space. 

It’s an innovative approach to using RNA-based vaccines for the first time in humans is not without controversy. This approach has been queried by many health professionals as too risque. And these concerns come at a time when all sorts of bugs seem to be coming at humanity from just about every angle. 

Its unique angle to creating vaccines using synthetic RNA might also be the “holy grail” of modern biotechnology. This could create the next generation of vaccines. 

Business News, Market News, News, Stocks, Wall Street
Christopher Hamman

Christopher Haruna Hamman is a Freelance content developer, Crypto-Enthusiast and tech-savvy individual. He is also a Superstar Content Developer, Strategy Demigod, and Standup Guy.

Related Articles